Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 312.90
-4.10 (-1.29%)
Aug 28, 2026, 4:59 PM CET
Zealand Pharma Ratios and Metrics
Market cap in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21,313 | 32,852 | 50,548 | 21,785 | 10,366 | 6,271 | |
Market Cap Growth | -28.60% | -35.01% | 132.03% | 110.16% | 65.31% | -28.46% |
Enterprise Value | 7,267 | 17,089 | 41,733 | 20,319 | 10,519 | 5,364 |
Last Close Price | 312.90 | 466.40 | 715.50 | 373.20 | 201.40 | 145.10 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.12 | 5.09 | - | - | - | - |
Forward PE | - | 3.95 | 38.43 | 151.81 | 115.37 | 115.37 |
PS Ratio | 4.59 | 3.57 | 806.30 | 63.55 | 99.69 | 57.77 |
PB Ratio | 1.18 | 2.22 | 5.87 | 13.68 | 12.71 | 6.76 |
P/TBV Ratio | 1.24 | 2.22 | 5.88 | 13.78 | 12.71 | 7.17 |
P/FCF Ratio | - | 5.06 | - | - | - | - |
P/OCF Ratio | - | 5.03 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.56 | 1.86 | 665.70 | 59.28 | 101.16 | 49.41 |
EV/EBITDA Ratio | 3.11 | 2.47 | - | - | - | - |
EV/EBIT Ratio | 3.15 | 2.47 | - | - | - | - |
EV/FCF Ratio | - | 2.63 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.05 | 0.08 | 0.64 | 0.85 |
Debt / EBITDA Ratio | 0.18 | 0.06 | - | - | - | - |
Debt / FCF Ratio | - | 0.06 | - | - | - | - |
Net Debt / Equity Ratio | -0.78 | -0.99 | -1.00 | -0.95 | -0.80 | -0.69 |
Net Debt / EBITDA Ratio | -6.04 | -2.12 | 6.88 | 2.73 | 0.90 | 0.83 |
Net Debt / FCF Ratio | 7.82 | -2.26 | 9.20 | 3.47 | 0.69 | 0.52 |
Asset Turnover | 0.25 | 0.72 | 0.01 | 0.20 | 0.06 | 0.06 |
Inventory Turnover | - | - | 0.85 | 0.69 | - | 0.12 |
Quick Ratio | 13.76 | 23.20 | 20.85 | 6.23 | 6.73 | 4.80 |
Current Ratio | 13.98 | 23.57 | 21.14 | 6.25 | 6.73 | 5.15 |
Return on Equity (ROE) | 16.31% | 55.06% | -21.13% | -58.43% | -110.75% | -69.99% |
Return on Assets (ROA) | 7.81% | 33.97% | -13.81% | -19.93% | -28.30% | -25.53% |
Return on Invested Capital (ROIC) | 101.93% | 1401.57% | -294.62% | -465.46% | -363.56% | -402.18% |
Return on Capital Employed (ROCE) | 12.50% | 45.30% | -13.90% | -33.10% | -60.70% | -45.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 12.86% | 19.65% | -2.13% | -3.23% | -11.60% | -16.24% |
FCF Yield | -8.43% | 19.78% | -1.86% | -2.01% | -9.20% | -19.68% |
Buyback Yield / Dilution | 0.27% | -7.70% | -17.40% | -22.49% | -7.77% | -11.73% |